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MaOBJECTIVES The aim of this study was to evaluate patient-reported and physician-assessed atrial ﬁbrillation
(AF)–related symptoms after AF ablation.
BACKGROUND Success of AF ablation is usually deﬁned as freedom from AF, although symptom relief is often
patients’ desire.
METHODS Symptom relief was assessed as perceived by patients using the short, validated, AF-speciﬁc symptom
questionnaire AF6 and as classiﬁed by physicians using the European Heart Rhythm Association (EHRA) classiﬁcation
at baseline and 6, 12, and 24 months after AF ablation. Recurrence of arrhythmia was documented by continuous
electrocardiographic monitoring.
RESULTS In total, 54 patients completed the 24-month follow-up. All 6 items on the AF6, AF6 sum score, and EHRA
class improved signiﬁcantly over time. The greatest improvement was seen during the ﬁrst 6 months after ablation, but
AF6 scores showed continued improvement up to 12 months, in contrast to EHRA class. There was a low correlation
between AF6 score and EHRA class, but the predictive ability was low. Both AF6 scores and EHRA class were signiﬁcantly
correlated with AF burden at all times after ablation. A change of >9 points in AF6 sum score corresponded to a
meaningful reduction in symptom severity.
CONCLUSION Patient-reported and physician-assessed outcomes were both useful in assessing symptom relief after AF
ablation, although patient-reported outcomes were more sensitive tools. There was also a discrepancy between patient-
reported and physician-assessed outcomes after ablation. Freedom from AF and a low AF burden most often resulted in a
reduction of symptoms, but symptom relief also occurred despite little effect on the arrhythmia. (J Am Coll Cardiol EP
2017;3:1168–76) © 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
EHRA = European Heart
Rhythm Association
ILR = implantable loop
recorder
IQR = interquartile range
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1169AF with minimal or no structural heart or other
serious disease. The most common success criterion
has been freedom from documented recurrence of
AF or other atrial tachyarrhythmias of more than
30 s in duration (1–3). In determining the impact
before and after ablation on symptoms and health-
related quality of life, generic rather than
AF-speciﬁc questionnaires have often been used (4).
However, although the main purpose and indication
for AF ablation is to reduce symptoms, the absence
or reduction of AF recurrence, regardless of the deﬁ-
nition and mode of follow-up, may not be an optimal
success criterion alone, because it does not reﬂect
what symptomatic patients experience.SEE PAGE 1177Electrocardiographic recordings are reliable in
detecting AF, but symptoms are not, even if the
patient suspects or believes that the symptoms are
caused by the arrhythmia (5). In addition, AF ablation
may also change the perception of AF so that a patient
may experience diminished symptoms despite
recurring episodes of arrhythmia (6,7). Studies also
suggest that physicians may underestimate patient
symptoms, especially when they are mild (8,9).
We hypothesized that patients and physicians
may rate the change in symptoms after ablation
differently. The aim of this study was to evaluate
patient-reported and physician-assessed AF-related
symptoms up to 2 years after AF ablation and to
identify whether they were correlated, in relation
to the AF burden continuously measured by an
implantable loop recorder (ILR).
METHODS
PATIENTS. Patients were enrolled at 2 Scandinavian
university hospitals and were eligible if they had: 1)
documented symptomatic paroxysmal or persistent
AF (<3 months) and were planned for catheter abla-
tion; and 2) were 30 to 70 years of age. Important
exclusion criteria were: 1) left atrial diameter >60
mm; 2) left ventricular ejection fraction <40%; 3)
signiﬁcant structural heart disease; and 4) contrain-
dication to oral anticoagulation. All patients gave
their written informed consent before enrollment in
the study. The study protocol was approved by the
appropriate ethical boards and was in compliance
with the Declaration of Helsinki.
The baseline evaluation included a physical
examination, laboratory tests, 12-lead electrocardi-
ography, echocardiography, and the completion of a
formally validated patient-related outcome form:
the AF-speciﬁc symptoms form AF6. All patientswere on long-term warfarin treatment with
a target international normalized ratio
between 2 and 3 for at least 4 weeks prior
to ablation. Patients remained on their
latest rhythm control medications during
and up to 3 months after ablation, when the
indication for rhythm control medication
was reassessed.DEVICE CHARACTERISTICS AND IMPLANT PROCEDURE.
Patients were implanted with an ILR (Reveal XT,
Medtronic, Minneapolis, Minnesota) in the left para-
sternal area at least 2 weeks before the ablation that
remained for a minimum of 24 months after ablation.
The autoactivation and the AF detection algorithm
were programmed to ON, which classiﬁes the heart
rhythm as AF when the R-R intervals within a 2-min
period show a certain pattern of uncorrelated irreg-
ularity (10). Patients were also encouraged to start
manually triggered 30-s rhythm recordings during
perceived arrhythmia symptoms using the patient
activator. The ILR was programmed to provide, over
time, the number of arrhythmia episodes, their
duration, and, when all durations of AF episodes were
added, the AF burden.
CATHETER ABLATION PROCEDURE. The catheter
ablation procedure has been reported previously (11)
and consisted of circumferential radiofrequency
lines around each pair of pulmonary vein ostia in
the left atrium. Reablation was permitted at the
investigator’s discretion without excluding the
patient from the study.
PATIENT-REPORTED OUTCOMES. Symptoms were
assessed using the AF-speciﬁc questionnaire AF6,
which has undergone thorough validation (12) and
testing of clinical responsiveness (13) and includes a
recall period of the most recent 7 days. This 6-item
questionnaire includes patient-reported AF-related
symptoms: item 1, “breathing difﬁculties at rest”; item
2, “breathing difﬁculties upon exertion”; item 3,
“limitations in day-to-day life due to AF”; item 4,
“feeling of discomfort due to AF”; item 5, “tiredness
due to AF”; and item 6, “worry/anxiety due to AF.”
A score of 0 (no symptoms) to 10 (severe symptoms) is
reported for each item, and all scores are added into a
single sum score. Sum scores range from 0 to 60, with
higher values reﬂecting more severe AF-related
symptoms. After initial instruction, the questionnaire
was completed by the patient without interaction from
physicians or nurses and before the electrocardiogram
was recorded to document the actual cardiac rhythm.
The AF6 questionnaire was completed before and 6, 12,
and 24 months after ablation.
TABLE 1 Baseline Patient Characteristics (N ¼ 57)
Male 34 (60.0)
Age, yrs 57  9
BMI (kg/m2) 29  5
Paroxysmal AF 50 (88.0)
Months from ﬁrst AF episode 57 (36–120)
Concomitant cardiovascular disease
Heart failure 2 (4.0)
Hypertension 24 (42.0)
Diabetes 2 (4.0)
Coronary artery disease 1 (2.0)
Valvular heart disease 1 (2.0)
Stroke/TIA 8 (14.0)
CHA2DS2-VASc scores
0 15 (26.0)
1 20 (35.0)
$2 22 (39.0)
Medications
Beta-blockers 37 (65.0)
Class I AADs 16 (28.0)
Class III AADs 16 (28.0)
Warfarin 42 (74.0)
Values are n (%), mean  SD, or median (interquartile range).
AAD ¼ antiarrhythmic drug; AF ¼ atrial ﬁbrillation; BMI ¼ body mass index;
CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $65 or 75 yrs,
diabetes, prior stroke or transient ischemic attack, vascular disease, female sex;
TIA ¼ transient ischemic attack.
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1170PHYSICIANS’ SYMPTOM EVALUATION. The physi-
cian categorized the patient’s condition according to
the European Heart Rhythm Association (EHRA)
classiﬁcation into class I (no symptoms), II (mild
symptoms: normal daily activity not affected), III
(severe symptoms: normal daily activity affected), or
IV (disabling symptoms: normal daily activity dis-
continued) during presumed arrhythmia episodes
depending on symptoms of palpitations, fatigue,
dizziness, dyspnea, chest pain, and anxiety (14).
EHRA class was noted before and 6, 12, and 24 months
after ablation.
AF BURDEN. The AF burden composed of adjudicated
AF episodes was calculated from the ILR data as the
percentage of time in AF between each follow-up visit,
as previously described. In addition to correlating the
AF burden with symptom scores, we applied a previ-
ously suggested AF burden cutoff limit of 0.5% at each
scheduled visit to deﬁne success of AF ablation (11,15).
STATISTICAL ANALYSIS. Categorical variables are
presented as percentages and continuous variables as
mean  SD or median (interquartile range [IQR]), as
appropriate. Friedman’s test was applied to evaluate
differences between time intervals for AF6 scores and
EHRA class. The McNemar test was used for binary
variables, and the Mann-Whitney U test was usedwhen comparing subgroups. The chi-square test or
Fisher exact test was used as appropriate. We
assessed the correlation of AF6 score before and after
ablation using the Pearson correlation coefﬁcient (r)
and all correlations involving AF burden, because of
non-normality, and EHRA class, because of the
ordinal scale, using the Spearman rank correlation
coefﬁcient (r). We also estimated the predictive abil-
ity by calculating the correlation coefﬁcient squared
(r2) as a measure of the proportion of variance
accounted for by the correlation. The distribution-
based Cohen effect size was used to estimate a
clinically important difference. The effect size was
interpreted according to standard criteria with trivial
(<0.20), small (0.20 to 0.49), moderate (0.50 to 0.79),
and large ($0.80) changes of baseline scores (16).
A p value of <0.05 was considered to indicate
statistical signiﬁcance. All statistical analyses
were performed using SPSS version 22 (IBM, Armonk,
New York).
RESULTS
BASELINE DEMOGRAPHICS. Fifty-nine patients were
screened, 1 withdrew consent, and 1 patient was
excluded because of a lack of a correlation between
AF and symptoms. Fifty-seven patients underwent AF
ablation and constituted the study population. Their
mean age was 57  9 years, and 40% were women.
The most common comorbidities were hypertension
(42%) and previous stroke or transient ischemic attack
(14%) (Table 1). Fifty-four patients completed the
24-month follow-up. Twenty-three patients (43%)
underwent reablation during follow-up.
PATIENTS’ ASSESSMENT OF AF-SPECIFIC SYMPTOMS
BEFORE AND AFTER ABLATION. Before ablation, AF6
items 1 to 6 scored $1 point in 54%, 83%, 83%, 91%,
85%, and 89% of the patients, respectively, and in
30%, 59%, 54%, 52%, 54%, and 54% of the patients at
24 months. The most severe symptom before abla-
tion was tiredness due to AF, which scored a median
of 7 of a maximum of 10 points (Table 2). When
symptoms persisted at 24 months, the most impor-
tant item was the same but showed statistically
signiﬁcantly reduced scores. All items on the AF6
and the sum score decreased statistically signiﬁ-
cantly over the 24-month follow-up period. The
median AF6 scores improved from before ablation to
6 months after ablation and further to 12 months for
all items and the sum score, except for item 1, and
remained at this level at 24 months after ablation.
The AF6 sum score at all times after ablation corre-
lated signiﬁcantly with the AF6 sum score before
TABLE 2 Patient and Physician Assessment of Atrial Fibrillation–Speciﬁc
Symptoms Before and After Ablation Using the AF6 and European Heart
Rhythm Association Classiﬁcation, Respectively
Before
Ablation 6 Months* 12 Months† 24 Months‡
p Value,
Friedman Test
AF6 item 1 1 (0–3) 0 (0–2) 1 (0–4) 0 (0–1) 0.001§
AF6 item 2 5 (2–8) 3 (0–7) 1 (0–4) 2 (0–6) 0.004§
AF6 item 3 5 (2–8) 2 (0–5) 1 (0–3) 1 (0–5) 0.001§
AF6 item 4 6 (3–8) 3 (0–6) 1 (0–3) 1 (0–6) <0.001§
AF6 item 5 7 (4–8) 5 (0–8) 2 (0–6) 2 (0–7) <0.001§
AF6 item 6 4 (2–6) 2 (0–5) 0 (0–3) 1 (0–3) <0.001§
AF6 sum 30 (17–38) 17 (2–30) 7 (0–19) 9 (0–27) <0.001§
EHRA class I 19 (35.0) 41 (76.0) 38 (70.0) 44 (82.0) <0.001§
EHRA class II 22 (41.0) 10 (19.0) 14 (26.0) 7 (13.0) <0.001§
EHRA class III 12 (22.0) 3 (6.0) 2 (4%) 3 (6.0) <0.001
EHRA class IV 1 (2.0) 0 0 0 <0.001
Values are median (interquartile range) or n (%). All 6 items in the AF6, the AF6 sum score, and
EHRA class improved signiﬁcantly over time. AF6 item 1, “breathing difﬁculties at rest”; item 2,
“breathing difﬁculties upon exertion”; item 3, “limitations in day-to-day life due to AF”; item 4,
“feeling of discomfort due to AF”; item 5, “tiredness due to AF”; and item 6, “worry/anxiety due to
AF.” A score of 0 (no symptoms) to 10 (severe symptoms) is reported for each item, and all scores
are added to give a single sum score of 0 to 60. EHRA class I (no symptoms), II (mild symptoms),
III (severe symptoms), or IV (disabling symptoms). *1 patient missing. †5 patients missing.
‡1 patient missing. §Statistically signiﬁcant (p < 0.05).
AF ¼ atrial ﬁbrillation; EHRA ¼ European Heart Rhythm Association.
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1171ablation (Figures 1A to 1C) (r ¼ 0.50 [p < 0.001],
r ¼ 0.38 [p ¼ 0.008], and r ¼ 0.28 [p ¼ 0.04], 6, 12,
and 24 months after ablation, respectively).
There were 11 (20%), 12 (22%), and 16 (30%)
patients, respectively, who reported no symptoms at
all (AF6 score 0) at 6, 12, and 24 months after ablation.
Five patients (9%) did not report any symptoms at
any time after ablation.
The mean AF6 sum score was 29.5  13.9 before
ablation. The mean difference in the AF6 sum score
from before ablation was 9.3 (95% conﬁdence inter-
val: 5.2 to 13.4; p < 0.001) at 6 months after ablation,
16.6 (95% conﬁdence interval: 12.2 to 20.9; p < 0.001)
at 12 months, and 13.6 (95% conﬁdence interval: 9.0
to 18.3 (p < 0.001) 24 months after ablation, corre-
sponding to Cohen effect sizes of 0.67, 1.2, and 0.98,
respectively. Thus, effect sizes were moderate to
large after ablation. An improvement of more than 9
points was therefore considered clinically meaningful
and was seen in 25 patients (50%) at 6 months, 33
patients (75%) at 12 months, and 30 patients (61%) at
24 months after ablation.
PHYSICIANS’ EVALUATION OF SYMPTOMS BEFORE AND
AFTER ABLATION: EHRA CLASSIFICATION. EHRA class
improved statistically signiﬁcantly over the 2-year
follow-up period, and at 6, 12, and 24 months
after ablation, 76%, 70%, and 82% of patients,
respectively, were in EHRA class I (Table 2). The
greatest improvement was seen during the ﬁrst
6 months after ablation, with no further improvement
beyond that period. EHRA class most often improved
by 1 class (from II to I, n ¼ 20; from III to II, n ¼ 1)
and less often by 2 or 3 classes (from III to I, n ¼ 10;
from IV to I, n ¼ 1).
Nineteen patients (35%) were already categorized
in EHRA class I before ablation, and 9 of them were
also considered to be in EHRA class I at all times after
the ablation. The remaining 10 patients varied from
EHRA class I to III after ablation; at 24 months, 4
patients were in EHRA class I, 4 in EHRA class II, and
2 in EHRA class III.
PATIENTS’ VERSUS PHYSICIANS’ EVALUATION OF
SYMPTOMS. The AF6 sum score decreased with
improving EHRA class, showing a signiﬁcant correla-
tion at 6 months (r ¼ 0.48, r2 ¼ 0.23; p < 0.001), 12
months (r ¼ 0.58, r2 ¼ 0.34; p < 0.001), and 24 months
after ablation (r ¼ 0.27, r2 ¼ 0.07; p ¼ 0.049).
The changes in AF6 sum score and EHRA class from
before ablation were visualized with scatterplots at
6 (r ¼ 0.31, r2 ¼ 0.10; p ¼ 0.02), 12 (r ¼ 0.32, r2 ¼ 0.10;
p ¼ 0.03), and 24 months (r ¼ 0.22, r2 ¼ 0.05; p ¼ 0.12)
after ablation (Figures 2A to 2C). In Figure 2A, 25
patients decreased in AF6 sum score by more than 9points, and nearly two-thirds of them also had a 1- or
2-class change in EHRA score. However, 12 patients
had smaller changes in AF6 sum score, and one-third
of them still had 1- or 2-class EHRA score changes,
implying that physicians had a more positive inter-
pretation of symptom improvement than patients.
Patients considered to be improved in EHRA class had
statistically signiﬁcantly lower median AF6 sum
scores of 1 (IQR: 0 to 4), 6 (IQR: 0 to 13), and 5 (IQR:
0 to 28) at 6, 12, and 24 months after ablation,
respectively, compared with patients with unchanged
or worse EHRA class with median AF6 sum scores
of 40 (IQR: 27 to 46; p ¼ 0.003), 31 (IQR: 12 to 39;
p ¼ 0.001), and 36 (IQR: 28 to 36; p ¼ 0.02).
The 19 patients (paroxysmal AF, n ¼ 15; persistent
AF, n ¼ 4) considered to be in EHRA class I before
ablation had a median AF6 sum score of 24 (IQR: 14 to
34) before ablation. The most common AF6 items
were limitations in day-to-day life due to AF and
worry/anxiety due to AF, while the highest scoring
item was tiredness due to AF.
EFFECT OF ABLATIONON AFOVER TIME IN RELATION TO
SYMPTOMS. The proportion of patients with AF
burden of 0% during the past 6-month period was
26%, 43%, and 43% at 6, 12, and 24 months after
ablation, increasing to 46%, 56%, and 65% if an AF
burden cutoff of #0.5% was applied. The proportion
of patients with AF burden #0.5% increased from
before ablation to 6 (p ¼ 0.01), 12 (p ¼ 0.01), and
FIGURE 1 Scatterplot Comparing the AF6 Sum Score Before and After Ablation
A B
C
(A) 6 months (r ¼ 0.50; p < 0.001, n ¼ 50), (B) 12 months (r ¼ 0.38; p ¼ 0.008, n ¼ 44), and (C) 24 months (r ¼ 0.28; p ¼ 0.04, n ¼ 49) after ablation. Patients above
the line of identity had worsened and patients below the line improved scores following ablation. Atrial ﬁbrillation burden is deﬁned as <0.5% (blue circles) or >0.5%
(green circles).
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117224 (p ¼ 0.004) months after ablation. There was a
small but not signiﬁcant decrease in median AF
burden over time (11).
The AF6 sum score was signiﬁcantly correlated with
AF burden at 6 (r¼0.37; p<0.01), 12 (r¼0.62; p<0.01),and 24 (r ¼ 0.52; p < 0.01) months after ablation. When
the AF burden cutoff of >0.5% was applied, there was
also a signiﬁcant association with higher AF6 sum
scores at all times after ablation (Figure 3). EHRA
class and AF burden were signiﬁcantly correlated at
FIGURE 2 Scatterplot Comparing Changes in AF6 Sum Score and European Heart Rhythm Association Class Before and After Ablation
A B
C
(A) 6 months (r ¼ 0.31, r2 ¼ 0.10; p ¼ 0.02), (B) 12 months (r ¼ 0.32, r2 ¼ 0.10; p ¼ 0.03), and (C) 24 months (r ¼ 0.22, r2 ¼ 0.05; p ¼ 0.12) after ablation. Negative
values indicate improvement and positive values deterioration. Patients in the lower left quadrant show improvement and in the upper right quadrant worsening in both
AF6 score and European Heart Rhythm Association (EHRA) class, while patients with discordant results are found in the upper left and lower right quadrants.
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11736 (r ¼ 0.35; p ¼ 0.01), 12 (r ¼ 0.42; p ¼ 0.002), and
24 (r ¼ 0.44; p ¼ 0.001) months after ablation.
The actual AF burden in the subgroup of patients
with AF burden >0.5% during the period 18 to
24 months after ablation (n ¼ 19) varied between
0.53% and 100%. All patients with an AF burden up to
9% improved in EHRA class (n ¼ 7) compared with
before ablation or remained in EHRA class I (n ¼ 4)
(Table 3). Six patients improved more than 9 points in
the AF6 sum score from baseline, compared with 25
patients with AF burden #0.5% at 24 months.When examining the 14, 23, and 23 patients with
AF burden of 0% at 6, 12, and 24 months after abla-
tion, the median AF6 sum score was low, and the IQR
showed a relatively wide range (6-month median,
0 [IQR: 0 to 27]; 12-month median, 0.5 [IQR: 0 to 7];
24-month median, 0 [IQR: 0 to 11]). The most com-
mon AF6 item was worry/anxiety due to AF, and the
highest ranking item was tiredness due to AF. Pa-
tients without any AF at any time after ablation were
categorized into EHRA class I in 100%, 91%, and 96%
at 6, 12, and 24 months after ablation, respectively.
TABLE 3 Patients With an Atrial Fibrillation Burden >0.5% 18 to 24 Months After
Atrial Fibrillation Ablation
Patient # AF Burden
EHRA Class
Before Ablation
EHRA Class,
24 Months
AF6 Sum Before
Ablation (Median)
AF6 Sum,
24 Months (Median)
1 0.53% I I 37 12
2 0.55% II I 2 2
3 0.8% II I 10 27
4 1% I I 34 27
5 1% III II 33 32
6 2% II I 16 5
7 2% II II 41 36
8 3% I I 15 0
9 5% I I 19 39
10 5% II I 27 27
11 9% II I 16 21
12 9% II I 53 28
13 18% I I 41 -
14 27% I III 21 26
15 71% III III 40 38
16 100% I II 36 20
17 100% II I 31 30
18 100% II II 47 28
19 100% I II 17 20
AF ¼ atrial ﬁbrillation; EHRA ¼ European Heart Rhythm Association.
FIGURE 3 Boxplot Showing a Signiﬁcant Difference Versus Baseline
in the AF6 Sum Score at 6, 12, and 24 Months Between Patients With
Atrial Fibrillation Burden #0.5% and >0.5% (p ¼ 0.005; p < 0.001;
and p < 0.001)
Boxes show the 25th and 75th percentiles. Horizontal lines within boxes
show the median; whiskers indicate minimum and maximum, and outliers are
plotted as circles.
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1174PAROXYSMAL VERSUS PERSISTENT AF. When
comparing the 7 patients with persistent AF before
ablation with the 47 with paroxysmal AF, we detected
no signiﬁcant difference in AF6 sum scores before or
after ablation and no difference in the proportion of
patients considered to be in EHRA class $II between
the groups.
DISCUSSION
In the present study, patients were followed by
patient-reported symptoms using the AF6 and
physician-assessed EHRA class for 2 years after AF
ablation with complete knowledge of the underlying
rhythm. AF ablation led to long-lasting symptom
relief as perceived both by patients and by physi-
cians, and AF burden correlated with both AF6 sum
score and EHRA class, especially when AF burden
was low. However, there was often a discrepancy
between AF6 sum score and EHRA class, implying
that physicians were more likely to indicate
improvement in terms of a better EHRA class, while
the AF6 appeared to be a more sensitive tool. Com-
plete freedom from AF did not preclude that patients
felt some symptoms, while patients with AF burden
up to 10% at 24 months indicated symptomatic
reduction after ablation.
PATIENT-REPORTED OUTCOMES USING THE
AF6. Disease-speciﬁc questionnaires have been
developed for AF but have not often been used after
ablation. We used the AF-speciﬁc AF6 and demon-
strated signiﬁcantly lower AF6 scores 24 months
after ablation compared with before, which is in line
with previous studies using disease-speciﬁc assess-
ment tools (17,18). The AF6 sum scores before and
after ablation were correlated; that is, the patients
with the highest scores before ablation also had the
highest scores after ablation, which still allowed
considerable reductions in the scores. Using the
Cohen effect size, we found a reduction of more
than 9 points to represent a moderate effect size,
which we accepted as a clinically meaningful
change and was observed in more than one-half of
the patients during follow-up. In patients with AF
recruited from tertiary care facilities, Dorian et al.
(19) found the minimal clinically important differ-
ence of the Atrial Fibrillation Effect on Quality of
Life questionnaire score to be 19 points after
3-month follow-up.
PATIENT-REPORTED OUTCOMES VERSUS AF BURDEN. AF
burden was low at all times after AF ablation, while
symptomatic relief improved over time. The AF6 sum
score had improved considerably at 6 months and
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1175improved further at 12 months, remaining at that level
during the rest of the follow-up period. Because the
continued improvement was not caused by a further
reduction of AF burden, an adaptation seems to have
occurred, possibly partly because patients needed
time to get used to fewer symptoms and less worry
and anxiety because of a lower risk for recurrent
AF episodes. AF6 scores were correlated with AF
burden after ablation. This ﬁnding contrasts with
studies using the Arrhythmia-Speciﬁc Questionnaire
in Tachycardia and Arrhythmia (18) and the AF
Symptom Severity Scale (20), in which no correlation
was found between AF burden and symptoms,
possibly because of the intermittent rhythm follow-up
using electrocardiography and Holter monitoring as
opposed to our continuous rhythm monitoring during
the entire follow-up period. Although patients with
AF burden >0.5% had higher AF6 scores, symptom
relief occurred in this group as well, either as judged
by the physician or as felt by the patient, but not often
by both at the same time. One-third of patients with
AF burden >0.5% at 24 months after ablation had a
clinically meaningful improvement in decreasing
their AF6 sum score by more than 9 points, but the
proportion was more than twice as high in patients
with AF burden #0.5%. Even patients with AF burden
of 0% after ablation had some AF6 sum scores,
although low, despite the theoretical impossibility of
having AF-speciﬁc symptoms without AF. The most
probable reason is that few, if any, symptoms are
unique in patients with AF. Interestingly, the most
common AF6 item in completely AF-free patients was
worry/anxiety due to AF.
PHYSICIAN ASSESSMENT: EHRA CLASS. Physician-
assessed EHRA class improved in the ﬁrst 6 months,
but not thereafter. A large study on the EHRA
classiﬁcation and the AF-speciﬁc Atrial Fibrillation
Effect on Quality of Life questionnaire in patients
with AF, although not ablation patients (9), found
that patients assessed as asymptomatic by physi-
cians reported AF-speciﬁc symptoms. This suggests
that physicians may underestimate symptoms when
they are mild, which is in line with the results of
our study. In another study, EHRA class correlated
well with Atrial Fibrillation Effect on Quality of Life
score but did not discriminate sufﬁciently in
patients with low-level symptoms in terms of
health-related utility (21). The investigators recom-
mended that EHRA class II should be divided into
2 subgroups on the basis of whether the patient is
troubled by symptoms of AF (class IIb) or not (class
IIa). Thus, our and other studies suggest adifference between what patients might perceive
and what physicians can detect. However, to our
knowledge, our study is the only to correlate these
ﬁndings with complete knowledge of the underlying
cardiac rhythm.
PHYSICIAN-ASSESSED OUTCOMES VERSUS AF
BURDEN. When the AF burden was #0.5% at
24 months, EHRA class was always improved, while
the results were less consistent in patients with AF
burden >0.5%. In the 19 patients with AF burden
>0.5%, 42% were reported to be improved by 1 EHRA
class. Thus, the physician-assessed EHRA class
correlated well with AF burden when the burden was
very low but not when AF burden was higher.
PATIENT-REPORTED VERSUS PHYSICIAN-ASSESSED
OUTCOMES. In contrast to the physician-assessed
EHRA class, the patient-reported AF6 scores showed
continued improvement up to 12 months after
ablation, indicating that AF6 is a more sensitive tool
for measuring symptoms. Despite a low correlation
between EHRA class and AF6 sum score, the predic-
tive ability was low, and the change in EHRA class
was not concordant with the change in the AF6 sum
score in nearly one-half of the patients, demon-
strating a discrepancy between physicians’ and
patients’ assessments of AF-speciﬁc symptoms.
HOW CAN PATIENTS BEST BE INVOLVED IN DECISIONS
ABOUT TREATMENT? Recently updated guidelines
advocate more patient involvement in decisions
about how to treat AF, both when selecting drugs for
rhythm and/or rate control and when deciding for or
against AF ablation (2). Decisions regarding rhythm
(and/or rate) control, including ablation, are based on
symptomatology in relation to the type of AF and its
duration as well as beneﬁts and risks in individual
patients. Symptoms are most often what bring
patients to their doctors, and the way they verbally
express and explain their symptoms may differ a
great deal. A short, informative, and validated
symptom score may add signiﬁcant information and
be of help in the selection of treatment.
STUDY LIMITATIONS. The study population was
small, but all patients were followed in great detail
for a minimum of 2 years, and our conclusions should
be considered hypothesis generating. The ILR was
implanted only a few weeks before ablation, and the
AF burden before ablation may therefore not be
entirely reliable. The AF6 was formally validated
using a recall period of 7 days, while no such period
has been indicated for EHRA class, meaning that any
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
perception of outcomes after AF ablation differs a great
deal between patients and their physicians, which
emphasizes that patient-reported outcomes should be
a primary aim of AF ablation done in order to evaluate
symptom relief and improve health-related quality of
life. A short, validated AF-speciﬁc symptom score
such as the AF6 provides greater patient input to the
evaluation of the results of AF ablation.
TRANSLATIONAL OUTLOOK: Routine use of an
AF-speciﬁc instrument may help provide optimal
individualized treatment from the patient’s point of
view. Additional studies may also show the value of
such an instrument in other AF patient populations
and/or after other interventions than AF ablation.
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made with caution.
CONCLUSIONS
Patient-reported and physician-assessed outcomes
both correlated with AF burden after AF ablation, but
there were frequent discrepancies between patients
and the physicians, especially at higher AF burdens.
Freedom from AF and a low AF burden resulted most
often in a reduction of symptoms, but symptom relief
also occurred despite little effect on the arrhythmia.
A short, validated AF-speciﬁc symptom score such as
the AF6 may provide greater patient input to the
evaluation of treatment for AF.
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